Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

AAA Receives GMP Approval for Lutate

By Drug Discovery Trends Editor | December 16, 2010

Advanced Accelerator Applications (AAA), an emerging international leader in molecular nuclear medicine, announced that it has received GMP (Good Manufacturing Practice) approval for the manufacture of Lutate, a radioactively labelled peptide that can be used to treat metastatic GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs).

The approval by the Italian Pharmaceutical Regulatory Authority (AIFA) will enable AAA to manufacture Lutate at its facility in Colleretto Giacosa, near Turin, Italy, making it the first industrial facility in the world approved to produce radio-labelled peptides for molecular nuclear therapy.

Neuroendocrine tumors are a rare group of tumors that start in the cells of the neuroendocrine system, a network of endocrine glands and cells throughout the body. Most GastroEnteroPancreatic tumors (GEPs) develop in the digestive system, usually starting in the stomach, bowel or pancreas. 

Lutate,177Lutetium?DOTA0-Tyr3-Octreotate, is a radiolabeled somatostatine analog which selectively targets somatostatine receptors which are over-expressed in tumor cells. The product was developed by AAA’s wholly-owned subsidiary, BioSynthema Inc, based in St Louis, Missouri, USA.

Lutate has been shown to be an effective and safe treatment for GEP-NETs in an investigator-sponsored clinical study at the Erasmus Medical Center, Rotterdam,  Netherlands, where over 600 patients have been treated with this innovative radiopharmaceutical. The study showed Lutate extended patients’ lives by between 3.5 and six years in comparison to current treatments, including chemotherapy. It was also shown to significantly improve quality of life, as measured by a number of function and symptom scales, especially in patients with proven tumor regression.

The US Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) have indicated the need for a Phase III study in order to prepare Lutate for registration. AAA has started a Parallel Scientific Advice (PSA) from the EMEA and FDA to discuss its Phase III protocol. The PSA system was introduced in 2006 to allow both agencies to exchange scientific views during the development phase of new drugs. AAA hopes to start a multicenter Phase III study in 2011 in both Europe and the United States, with potential approval anticipated in 2015.

Lutate has been granted Orphan Drug status by both the FDA and EMEA, which gives it protection from competition for seven years in the US and 10 years in Europe following approval.

Stefano Buono, Chief Executive Officer of AAA, commented “We hope that manufacturing Lutate for clinical study use and the absence of a valid therapeutic alternative will open up the possibility of treating patients in many countries during the registration phase. We anticipate that the Colleretto Giacosa site and a second potential facility for the production of Lutate and other Radio Metabolic Therapies at the IRST (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori) in Meldola, Italy, would be able to produce sufficient quantities of Lutate to meet European demand, as well as developing new drugs.”

Dr. Jack Erion, CEO of BioSynthema, added, “Since merging with AAA we have reformulated Lutate to facilitate its use as a ready-to -use injectable drug. We have requested a Parallel Scientific Advice from EMA and FDA to discuss the Phase III protocol as this relatively new procedure seems particularly adapted to the development of Orphan Drugs”.

Date: December 16, 2010
Source: Advanced Accelerator Applications 


Filed Under: Drug Discovery

 

Related Articles Read More >

Sai Life Sciences exec: GLP-1 boom has ‘exploded the peptide field’ as firm opens new center
Novartis in the Pharma 50
Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE